Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PTEN deletion is rare but often homogeneous in gastric cancer.
Mina S, Bohn BA, Simon R, Krohn A, Reeh M, Arnold D, Bokemeyer C, Sauter G, Izbicki JR, Marx A, Stahl PR. Mina S, et al. Among authors: krohn a. J Clin Pathol. 2012 Aug;65(8):693-8. doi: 10.1136/jclinpath-2011-200525. Epub 2012 May 25. J Clin Pathol. 2012. PMID: 22639407
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.
Kluth M, Harasimowicz S, Burkhardt L, Grupp K, Krohn A, Prien K, Gjoni J, Haß T, Galal R, Graefen M, Haese A, Simon R, Hühne-Simon J, Koop C, Korbel J, Weischenfeld J, Huland H, Sauter G, Quaas A, Wilczak W, Tsourlakis MC, Minner S, Schlomm T. Kluth M, et al. Among authors: krohn a. Int J Cancer. 2014 Sep 15;135(6):1369-80. doi: 10.1002/ijc.28784. Epub 2014 Apr 26. Int J Cancer. 2014. PMID: 24523142 Free article.
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, Izbicki JR, Pantel K, Dikomey E, Korbel JO, Plass C, Sauter G, Schlomm T, Minner S. Kluth M, et al. Among authors: krohn a. Mod Pathol. 2013 Jul;26(7):975-83. doi: 10.1038/modpathol.2012.236. Epub 2013 Feb 1. Mod Pathol. 2013. PMID: 23370768 Free article.
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T. Minner S, et al. Among authors: krohn a. Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791629
CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.
Burkhardt L, Fuchs S, Krohn A, Masser S, Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, Schlomm T, Minner S, Sauter G, Sirma H, Simon R. Burkhardt L, et al. Among authors: krohn a. Cancer Res. 2013 May 1;73(9):2795-805. doi: 10.1158/0008-5472.CAN-12-1342. Epub 2013 Mar 14. Cancer Res. 2013. PMID: 23492366
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T. Krohn A, et al. Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13. Am J Pathol. 2012. PMID: 22705054
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H. Krohn A, et al. J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223. J Pathol. 2013. PMID: 23794398
94 results